Pfizer recruits new Group Head of Oncology R&D

pharmafile | June 6, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Pfizer has said Dr Jeff Settleman will join the firm as the company’s new Senior Vice President and Group Head of Oncology Research & Development.

Dr Settleman, who will lead all early oncology research, will report to Dr Mikael Dolsten, Pfizer’s Chief Scientific Officer and President of Worldwide Research, Development and Medical at the firm’s La Jolla, California facilities.

“Dr Settleman brings to Pfizer a breadth of experience in fundamental cancer biology, cancer genetics, and innovative thinking related to the role of tumour heterogeneity in the development of drug tolerance and resistance. I look forward to seeing his expertise help Pfizer further accelerate potential breakthroughs for people living with cancer,” said Dr Dolsten.

“Dr Settleman’s distinguished career in both academic research and drug discovery will be critical to Pfizer’s continuous pursuit of new therapeutic paradigms in cancer research.”

Dr Settleman is joining Pfizer from the Google-backed biotech Calico Life Sciences where he was head of Oncology Research. Prior to Calico, Dr Settleman led Discovery Oncology at Genentech.

Dr Settleman made the move into the lifesciences industry after establishing a career in academia through positions at Harvard Medical School and the Whitehead Institute for Biomedical Research at Massachusetts Institute of Technology (MIT).

Commenting on his appointment, Dr Settleman said: “I am privileged to be joining a world-class team of scientists who have made many important contributions to the landscape of cancer treatments for patients over several decades.”

“There has never been a more exciting time in cancer research and I look forward to helping advance and grow a highly promising pipeline that includes a variety of targeted therapies and immunotherapies, with opportunities for rational combination treatments.”

Dr Settleman’s appointment comes after Dr Robert Abraham, who has led Pfizer’s Oncology Research & Development at 2011, announced he would be retiring from his position at the end of 2019.

Related Content

No items found

Latest content